We are live on ! Find out more

Medline Inc

MDLN

Market cap $37B

42.15 USD

+1.24

3.03%

At close Updated Nov 11, 3:59 PM EST

Pre-market

After hours

42.02

-0.13

0.31%

1 day

3.03%

5 days

4.82%

1 month

17.87%

3 months

20.29%

6 months

7.39%

Year to date

3.77%

1 year

2.8%

5 years

2.8%

10 years

2.8%

About: Medline is the largest provider of medical-surgical products and supply chain solutions in the US. The company generates over 90% of its revenue domestically and serves some of the largest US health systems. Medline offers approximately 190,000 Medline-branded products across more than 250 product families—including front-line care, surgical solutions, and laboratory and diagnostics—as well as roughly 150,000 third-party products sourced from over 1,250 vendors. The company maintains prime vendor relationships with many customers, acting as the primary consolidated logistics partner for their medical-surgical needs. Medline has significant scale, supported by more than 30 manufacturing facilities and a fleet of over 2,000 owned delivery trucks. Medline went public in December 2025.

Employees: 45,000

Healthcare Medical Instruments & Supplies

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 1.3%

Neutral 97.4%

Negative 1.3%

MDLN Securities Notice: Medline Investors that Suffered Losses when Stock Plummeted 13% are Notified to Contact BFA Law about its Securities Fraud Investigation

NEW YORK, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Medline Inc. (NASDAQ:MDLN) for potential securities fraud after its significant stock drops. If you invested in Medline securities, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/medline-class-action-lawsuit.

MDLN Securities Notice: Medline Investors that Suffered Losses when Stock Plummeted 13% are Notified to Contact BFA Law about its Securities Fraud Investigation

Medline Q3 Earnings Call Highlights

Medline NASDAQ: MDLN reported third-quarter revenue growth of 10% year over year to $7.9 billion, supported by broad-based gains across its Medline Brand and Supply Chain Solutions businesses. Adjusted EBITDA increased 12% to $1 billion, while the company raised its full-year organic sales growth outlook for a third consecutive quarter.

Medline Q3 Earnings Call Highlights

Zacks Investment Research

Medline (MDLN) Reports Q3 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Medline (MDLN) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Medline (MDLN) Reports Q3 Earnings: What Key Metrics Have to Say

Medline Reports Third Quarter and Nine Months 2026 Results

NORTHFIELD, Ill., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline” or the “Company”) (Nasdaq: MDLN), the largest provider of medical-surgical (“med-surg”) products and supply chain solutions serving all points of care3, today reported its operating results for the three and nine months ended September 26, 2026.

Medline Reports Third Quarter and Nine Months 2026 Results

MDLN Investigation Reminder: Medline Product Quality Issues Trigger Securities Fraud Investigation for Investors – Contact BFA Law if You Lost Money

NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Medline Inc. (NASDAQ:MDLN) for potential securities fraud after its significant stock drops. If you invested in Medline securities, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/medline-class-action-lawsuit.

MDLN Investigation Reminder: Medline Product Quality Issues Trigger Securities Fraud Investigation for Investors – Contact BFA Law if You Lost Money

Medline announces participation in the 2026 Jefferies Global Healthcare Conference

NORTHFIELD, Ill., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline”) (Nasdaq: MDLN) today announced that Jim Boyle, chief executive officer, is scheduled to present at the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, at 3:30pm Greenwich Mean Time (GMT).

Medline announces participation in the 2026 Jefferies Global Healthcare Conference

MDLN Stock Market Alert: Medline Under Investigation for Potential Securities Fraud Over Product Quality Issues – Contact BFA Law if You Lost Money

NEW YORK, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Medline Inc. (NASDAQ:MDLN) for potential securities fraud after its significant stock drops. If you invested in Medline securities, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/medline-class-action-lawsuit.

MDLN Stock Market Alert: Medline Under Investigation for Potential Securities Fraud Over Product Quality Issues – Contact BFA Law if You Lost Money

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Medline Inc. - MDLN

NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Medline Inc. - MDLN

$MDLN Stock Market Alert: Medline Investigated for Securities Fraud after Product Quality Issues Lead to 13% Stock Drop – Contact BFA Law if You Lost Money

NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Medline Inc. (NASDAQ:MDLN) for potential securities fraud after its significant stock drops. If you invested in Medline securities, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/medline-class-action-lawsuit.

$MDLN Stock Market Alert: Medline Investigated for Securities Fraud after Product Quality Issues Lead to 13% Stock Drop – Contact BFA Law if You Lost Money

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Medline Inc. - MDLN

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Medline Inc. (“Medline” or the “Company”) (NASDAQ: MDLN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Medline Inc. - MDLN

See News Rankings

Price charts implemented using Lightweight Charts™